{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix D Examples of CYP substrates with narrow therapeutic range', 'CYP ENZYMES', 'SUBSTRATES WITH NARROW THERAPEUTIC RANGE(1', 'CYP1A2', 'THEOPHYLLINE, TIZANIDINE', 'CYP2C8', 'PACLITAXEL', 'CYP2C9', 'WARFARIN, PHENYTOIN', 'CYP2C19', 'S-MEPHENYTOIN', 'CYP3A(2', 'ALFENTANIL, ASTEMIZOLE\u00b3, CISAPRIDE\u00b3, CYCLOSPORINE(4,', 'DIHYDROERGOTAMINE, ERGOTAMINE, FENTANYL, PIMOZIDE,', 'QUINIDINE, SIROLIMUS, TACROLIMUS(4, TERFENADINE\u00b3', 'CYP2D6', 'THIORIDAZINE', 'Note that this is not an exhaustive list. For an updated list, see the following link:', 'http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabelin', 'g/ucm080499.htm.', '(1) CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship', 'indicates that small changes in their exposure levels by the concomitant use of CYP inhibitors or inducers', 'may lead to either serious safety concerns (eg, Torsades de Pointes) or loss of therapeutic effect.', '(2) Because a number of CYP3A substrates (eg, darunavir, maraviroc) are also substrates of P-gp, the', 'observed increase in exposure could be due to inhibition of both CYP3A and P-gp.', '(3) Withdrawn from the United States market because of safety reasons', '(4) Prohibited medication during the study', 'Property of the Sanofi Group - strictly confidential', 'Page 140', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix E Asthma Symptom Score Numerical Rating Scale (NRS)', 'Property of the Sanofi Group - strictly confidential', 'Page 141', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix F', 'Asthma Control Questionnaire-Interviewer Administered (ACQ-IA)', 'for Children 6 to <12 years', 'Asthma Control Questionnaire, 7-question version (ACQ-7)', 'The Asthma Control Questionnaire: Interviewer-Administered (ACQ-IA) is', 'c', 'copyrighted and all rights are reserved. No part of this questionnaire may', 'be sold, modified or reproduced without the express permission of', 'Elizabeth Juniper on behalf of QOL Technologies Ltd', 'JULY 2011', 'ACQ-IA - North American /English-revised July 2011', 'ID5133/ACQ-IA_AU1.O_eng-US/CAori.doc', 'Property of the Sanofi Group - strictly confidential', 'Page 142', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}